Every 10-Q that Neurogene, Inc. (NGNE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NGNE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NGNE filings page.
Neurogene Inc. is a clinical-stage biotech focused on gene therapies for severe neurological diseases, led by NGN‑401 for Rett syndrome. For the six months ended June 30, 2026, it reported a net loss of $65.4 million, widening from $44.7 million a year earlier, driven mainly by higher Rett clinical and manufacturing spend and increased stock‑based compensation.
Research and development expenses rose to $50.6 million, while general and administrative expenses increased to $19.4 million. Cash, cash equivalents and short‑term investments totaled $225.4 million at June 30, 2026, with net cash used in operating activities of $49.9 million.
Subsequent to quarter end, Neurogene completed a July 2026 underwritten offering of common stock and pre‑funded warrants, raising $143.8 million gross and $134.8 million net. Management states that, after this raise, existing cash and investments are expected to fund operations into the first quarter of 2029, supporting the ongoing registrational Embolden trial of NGN‑401 and manufacturing scale‑up activities.
Neurogene Inc. reported a larger net loss for the three months ended March 31, 2026 as it increased investment in its gene therapy pipeline. Net loss was $30.9 million compared with $22.6 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $25.2 million from $17.8 million, primarily reflecting increased clinical and manufacturing costs for NGN‑401, its Rett syndrome program. General and administrative expenses were stable at $8.2 million. Interest income declined as short‑term investments decreased and yields softened.
Neurogene ended March 31, 2026 with $243.2 million in cash, cash equivalents and short‑term investments and used $26.1 million of cash in operating activities during the quarter. Management expects existing capital to fund obligations for at least one year from the financial statement issuance date while it advances NGN‑401 and other early discovery efforts.
Neurogene Inc. (NGNE) filed its Q3 2025 10‑Q, reporting a net loss of $20.953 million as operating expenses rose with advancing gene therapy programs. Revenue was none. Research and development expense was $17.241 million and general and administrative expense was $6.557 million; other income contributed $2.845 million. Net loss per share was $0.99.
Liquidity remains strong with cash, cash equivalents and short‑term investments totaling $265.4 million as of September 30, 2025. Year‑to‑date operating cash use was $59.7 million. The company sold 500,000 shares via its at‑the‑market program for $9.8 million net in September, and subsequently raised $20.6 million net from 700,000 shares in October.
Program updates: the registrational Embolden trial of NGN‑401 for Rett syndrome began dosing its first participant in Q4 2025 after FDA alignment on key design elements; NGN‑401 holds RMAT designation and is in FDA’s START pilot. Interim Phase 1/2 data (pediatric cohort at the 1E15 vg dose) showed multidomain developmental gains and a tolerability profile with only Grade 1–2 treatment‑related AEs. Shares outstanding were 14,775,285 as of September 30, 2025; 15,489,800 as of November 11, 2025.